These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 15490387)
1. Meningovascular syphilis and improvement with tissue-plasminogen activator (T-PA). Han JH; Lee CC; Crupi RS Am J Emerg Med; 2004 Sep; 22(5):426-7. PubMed ID: 15490387 [No Abstract] [Full Text] [Related]
2. Should a hospital without a neurologist use t-PA to treat stroke? Krieger DW Cleve Clin J Med; 1999; 66(10):585-6. PubMed ID: 10598361 [No Abstract] [Full Text] [Related]
3. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy. Collen D Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986 [No Abstract] [Full Text] [Related]
4. Serine-proteases as plasminogen activators in terms of fibrinolysis. Flemmig M; Melzig MF J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207 [TBL] [Abstract][Full Text] [Related]
5. [Structure, function and use of fibrinolysis-promoting and inhibiting factors]. Bachmann F Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901 [TBL] [Abstract][Full Text] [Related]
6. Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction. Gurbel PA; Dalesandro MR; Serebruany VL Thromb Haemost; 1998 Oct; 80(4):725. PubMed ID: 9799011 [No Abstract] [Full Text] [Related]
8. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Gurewich V; Pannell R Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707 [No Abstract] [Full Text] [Related]
15. Pharmacology of thrombolytic drugs. Verstraete M; Collen D J Am Coll Cardiol; 1986 Dec; 8(6 Suppl B):33B-40B. PubMed ID: 3097100 [TBL] [Abstract][Full Text] [Related]
16. Validity of the GUSTO trial's main conclusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries. Eisenberg C Pharmacotherapy; 1997; 17(4):850-2. PubMed ID: 9250573 [No Abstract] [Full Text] [Related]